Dopamine News and Research

RSS

Dopamine is a hormone and neurotransmitter occurring in a wide variety of animals, including both vertebrates and invertebrates. In the brain, this phenethylamine functions as a neurotransmitter, activating the five types of dopamine receptors — D1, D2, D3, D4 and D5, and their variants. Dopamine is produced in several areas of the brain, including the substantia nigra and the ventral tegmental area. Dopamine is also a neurohormone released by the hypothalamus. Its main function as a hormone is to inhibit the release of prolactin from the anterior lobe of the pituitary. Dopamine has many functions in the brain, including important roles in behavior and cognition, motor activity, motivation and reward, inhibition of prolactin production (involved in lactation), sleep, mood, attention, and learning. Dopaminergic neurons (i.e., neurons whose primary neurotransmitter is dopamine) are present chiefly in the ventral tegmental area (VTA) of the midbrain, substantia nigra pars compacta, and arcuate nucleus of the hypothalamus.

Study shows how Parkinson's spreads and leads to nerve cell death

Understanding how any disease progresses is one of the first and most important steps towards finding treatments to stop it. This has been the case for such brain-degenerating conditions as Alzheimer's disease. Now, after several years of incremental study, researchers at the Perelman School of Medicine, University of Pennsylvania have been able to piece together important steps in how Parkinson's disease (PD) spreads from cell to cell and leads to nerve cell death.

17 Nov 2012

Bradykinesia is ‘context-specific’ in Parkinson’s

Patients with Parkinson’s disease can make rapid responses to avoid adverse stimuli, but cannot speed up their actions to gain a reward, report UK researchers.

16 Nov 2012

Feinstein seeks NDA approval for Fluorodopa F 18 PET scan to diagnose parkinsonian syndromes

The Feinstein Institute for Medical Research announced today the submission of a New Drug Application to the US Food and Drug Administration (FDA) for the Fluorodopa F 18 positron emission tomography (PET) scan used to diagnose parkinsonian syndromes.

15 Nov 2012

AKT1 genotype influences risk of psychotic disorders in cannabis users

The ability of cannabis to produce psychosis has long been an important public health concern. This concern is growing in importance as there is emerging data that cannabis exposure during adolescence may increase the risk of developing schizophrenia, a serious psychotic disorder. Further, with the advent of medical marijuana, a new group of people with uncertain psychosis risk may be exposed to cannabis.

15 Nov 2012

Dopamine improves long-term memory

The feel-good hormone dopamine improves long-term memory. This is the finding of a team lead by Emrah D-zel, neuroscientist at the German Center for Neurodegenerative Diseases and the University of Magdeburg.

9 Nov 2012

Genetic underpinning of placebo effect identified

US researchers have identified a gene that appears to be responsible for the placebo effect.

1 Nov 2012

Additional data from EnVivo’s EVP-6124 Phase 2b trial on AD presented at CTAD meeting

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, today presented pharmacokinetic and pharmacodynamic data along with the previously reported statistically significant clinical results from its Phase 2b clinical trial of EVP-6124, a novel alpha-7 agonist, in patients with Alzheimer's disease.

1 Nov 2012

FDA accepts Sunovion’s two LATUDA sNDAs for review

Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two supplemental New Drug Applications (sNDAs) for the use of LATUDA as 1) monotherapy and 2) adjunctive therapy to lithium or valproate, both to treat adult patients with depressive episodes associated with bipolar I disorder (bipolar depression).

31 Oct 2012

Light-sensitive protein to study Parkinson's disease

Introducing a light-sensitive protein in transgenic nerve cells... transplanting nerve cells into the brains of laboratory animals... inserting an optic fibre in the brain and using it to light up the nerve cells and stimulate them into releasing more dopamine to combat Parkinson's disease...

29 Oct 2012

Omega-3 fatty acid can enhance cognition in highly functional young individuals

While Omega-3 essential fatty acids-found in foods like wild fish and grass-fed livestock-are necessary for human body functioning, their effects on the working memory of healthy young adults have not been studied until now.

26 Oct 2012

BioLineRx intends to conduct interim analysis of BL-1020 Phase II/III trial for schizophrenia

BioLineRx, a biopharmaceutical development company, announced today that it intends to conduct an interim analysis of the Phase II/III CLARITY trial of BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia.

25 Oct 2012

WSU researcher examines use of carbon fiber microelectrodes in neurochemical measurements

A Wayne State University researcher's take on the current state of brain chemical analysis is the cover story in a recent professional journal, accompanied by a podcast.

25 Oct 2012

Scientists create new compounds that could slow progression of Parkinson's

In an early-stage breakthrough, a team of Northwestern University scientists has developed a new family of compounds that could slow the progression of Parkinson's disease.

25 Oct 2012

Medication at end of life indicates care quality

Medication given to patients at the end of life varies according to whether they are being cared for in a hospice or hospital, and has the potential to indicate the quality of their care, suggest researchers.

24 Oct 2012

Exendin-4 could effectively treat addiction

Vanderbilt researchers are reporting today that a drug currently used to treat type 2 diabetes could be just as effective in treating addiction to drugs, including cocaine.

24 Oct 2012

Psychotic reactions associated with natural testosterone booster products

In a report published in the current issue of Psychotherapy and Psychosomatics a group of Italian investigators describe the case of a young men developing a psychotic reaction to natural testosterone booster products.

20 Oct 2012

Stem cell study may help to unravel how genetic mutation leads to Parkinson's symptoms

By reprogramming skin cells from Parkinson's disease patients with a known genetic mutation, researchers at the Salk Institute for Biological Studies have identified damage to neural stem cells as a powerful player in the disease.

20 Oct 2012

Nonmotor symptoms common in early-stage PD

Nonmotor symptoms occur in nearly all individuals with Parkinson’s disease, Italian study results suggest.

17 Oct 2012

Hereditary genes responsible for pain severity after motor vehicle collisions

Two studies presented at the ANESTHESIOLOGY 2012 annual meeting found that hereditary genes were responsible for the amount and type of pain experienced after a motor vehicle collision (MVC).

17 Oct 2012

Mephedrone and memory loss: an interview with Craig Motbey

Mephedrone is a fairly new designer drug which has been around for a few years. It exploded in popularity in Europe (and particularly in the UK) before it started to spread in a major way elsewhere.

16 Oct 2012